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Abstract. The aims of the present study were to determine 
whether the changes in density and location of CD68-positive 
and CD206-positive macrophages contribute to progression of 
hepatocellular carcinoma (HCC) and to evaluate prognostic 
values of these cells in post-surgical patients. A retrospec-
tive study involving 268 HCC patients was conducted. 
CD68-positive and CD206-positive macrophage infiltra-
tion in HCC tissues and adjacent tissues was examined by 
immunohistochemistry (IHC) and the relationship between 
the clinicopathological features and prognosis was analyzed. 
Receiver operating characteristics (ROC) curve was used 
to calculate diagnostic accuracy. There was an increase in 
CD68-positive and CD206-positive macrophage infiltration 
in adjacent tumor tissues compared with tumor tissues. ROC 
curve identified their optimal diagnostic cut-off values. The 
survival analysis showed that increased CD68 expression in 
adjacent tissues conferred superior overall survival (OS) and 
disease-free survival (DFS), while increase of CD206 in 
tumor yielded inferior OS and DFS. Cox regression analysis 
suggested both CD68-positive macrophages in adjacent area 
and intratumor CD206-positive macrophages as independent 
prognostic biomarkers for post-surgical HCC patients. Finally, 
a combination of CD68/CD206 and HBV-positive further 
improved prognostic stratification, especially in DFS. These 
results provide the first evidence for region- and subset-
dependent involvement of CD68 and CD206 cells in HCC 
progression. A combination of CD68/CD206 density and 
HBV-positivity improves further predictive value for post-
operative recurrence of HCC. Quantification of CD68/CD206 
macrophages and their distribution can be exploited for better 
postsurgical management of HCC patients. These findings 
provide a basis for developing novel treatment strategies aimed 
at re-educating macrophages in tumor microenvironment.
Introduction
Hepatocellular carcinoma (HCC) is one of the most lethal 
malignancies ranking as the fifth most common cancer 
worldwide (1). The incidence of advanced HCC cases who 
underwent multiple metastasis and dismal prognosis is 
increasing and usually the lack of effective treatment options 
will lead to serious social burdens (2). Currently, radical 
or partial hepatectomy represents the standard of care for 
patients with early diagnosis. However, distant metastases 
and postoperative relapse remain tremendous challenges. 
Therefore, identification of potential new therapeutic targets 
and prognostic biomarkers would be of great benefit to HCC 
patients.
Recent advance suggests that inflammation plays a critical 
role in carcinogenesis. As pivotal mediators in the inflam-
matory response, macrophages could generally be polarized 
into two principal subtypes: classically activated macrophages 
(M1) and alternatively activated macrophages (M2) (3). 
However, the two classes of macrophages play a diverse role 
in exhibiting pro- and anti-inflammatory activities, respec-
tively. Tumor-associated macrophages (TAMs) are recruited 
to tumors by various cytokines and growth factors (4). They 
are widely documented as a fundamental cellular compo-
nent within the tumor immune microenvironment, even 
having distinct phenotypes of TAMs at different stages of 
the tumor (5). TAMs substantially affect the fate of cancer 
cells and the clinical outcome by interacting in a compli-
cated manner with neoplastic cells (6,7). Generally, TAMs 
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are of M2-like phenotype and have a protumor role. This is 
supported by the evidence that these macrophages can promote 
tumor progression and metastasis by orchestrating tumor cell 
motility, invasion, angiogenesis and antitumor immunity (8,9). 
In majority of solid tumors, TAMs were often associated with 
decreased patient survival (10-12). Nonetheless, conflicting 
results have been observed by several investigators in some 
types of cancers, for example, non-small cell lung cancer and 
papillary renal cell carcinoma (13,14).
CD68 is commonly considered to be a pan-macrophage 
marker (15,16). However, CD68 cannot distinguish M1 or M2 
subtype from all the pan-macrophages (15). In addition to its 
existence in resident macrophages of multiple tissues, CD68 
is also expressed in tumor-infiltrating macrophages. CD206 is 
known to be expressed on the surface of most classes of macro-
phages and dendritic cell subpopulations, and is routinely 
used to identify the M2 phenotype (17). CD206 is involved 
in antigen presentation, endocytosis and phagocytosis, signal 
transduction, innate host defense and the adaptive immune 
response (18). To date, both CD68 and CD206 have been the 
subjects of extensive structural and functional investigation 
in human diseases, especially in tumors. The associations of 
CD68-positive or CD206-positive macrophages with poor 
prognosis have been extensively documented in various types 
of malignancies, such as oral squamous cell carcinoma, breast 
cancer and HCC (19-24). However, the clinical relevance of 
macrophages infiltration to distinct histologic locations to 
HCC prognosis remained unclear. A better understanding 
of the roles of CD68 and CD206 macrophages in HCC may 
provide valuable information for prevention and treatment of 
HCC. Herein, we initiated a comparative follow-up study to 
explore their distribution and expression, as well as prognostic 
value in primary HCC.
Materials and methods
Patients and specimens. A total of 268 anonymized patients 
with primary HCC were collected and pathologically 
confirmed by Pathology Department of the First Affiliated 
Hospital of Anhui Medical university were enrolled in the 
present study. All the patients aged >18 years underwent 
surgical curative resection with follow-up from October 2011 
to December 2016. Concurrence of other malignant diseases, 
autoimmune disease, syphilis and human immunodeficiency 
virus were excluded from the study. None of the cases received 
chemotherapy and/or radiotherapy previous to surgery. Total 
of 266 primary tumor tissues were grouped into case subjects 
and 243 tumor adjacent tissues were evaluated as the control 
group. Paired, formalin-fixed and paraffin-embedded (FFPE) 
primary tumor tissues and tumor adjacent tissues specimens 
were obtained from the whole patient population. This study 
was approved by the Human Research Ethics Committee of 
Anhui Medical university. Informed consents were obtained 
from all the participating patients.
In the present study, the hematoxylin and eosin slides 
were independently examined, and the histological diag-
noses were re-evaluated systematically by two experienced 
pathologists who were blinded to the clinical outcome of 
the samples based on WHO classifications of HCC. Clinical 
stages of tumor progression were determined according to 
the tumor-node-metastasis (TNM) classification system of the 
International union against Cancer/American Joint Committee 
on Cancer (IuAC/AJCC) (Edition 7). The following clinical 
data were obtained in a well-designed questionnaire, including 
TNM stage, demographics (sex and age), family history, 
alcohol consumption, laboratory data including alpha fetopro-
tein (AFP), serum albumin and total bilirubin (TBIL).
Reagents. The following primary antibodies were used: mouse 
anti-CD68 antibody (KP1) (cat. no. ab845), mouse anti-CD206 
antibody (cat. no. ab117644) and they were obtained from 
Abcam (Cambridge, MA, uSA). Anti-CD68 antibody was 
prediluted. The anti-CD206 antibody was applied at a dilu-
tion of 1:200. Both immunohistochemical MaxVision kit 
and diaminobenzidine (DAB) chromogenic reagent kit were 
purchased from Fuzhou Maixin Biotech, Co., Ltd. (Fuzhou, 
China).
Immunohistochemistry. We detected the expression of 
CD206 and CD68 in two different areas with IHC staining 
and further calculated their distribution densities. FFPE tissue 
sections (4 µm-thick) were processed for IHC staining with 
mouse anti-human CD68 antibody and mouse anti-human 
CD206 antibody as described. IHC assay was performed 
with MaxVision IHC kit and DAB chromogenic reagent kit. 
Briefly, the protocol was as described below. First, the tissue 
sections were deparaffinized and hydrated, immersed in 
ethylene diamine tetraacetic acid buffer (PH 8.0) and heated 
for 15 min in a microwave oven for antigen retrieval. Next, 
the primary antibody against CD68 or CD206 was added 
to the specimen sections at 4˚C and incubated overnight, 
which were then developed using the immunohistochemical 
MaxVision kit. The primary antibody was removed, and the 
secondary antibody was incubated with the samples (1:1,000) 
at 37˚C for 30 min. The kit solution was incubated with tissue 
samples at room temperature for 20 min, and thereafter, 
DAB chromogenic reagent was added. Finally, hematoxylin 
staining was carried out. The primary antibody was replaced 
with phosphate buffered saline, which was used as the nega-
tive control. IHC staining of positive samples was repeated 
twice. 
Counting. The tan or brown granules in the cytoplasm of 
cancer or adjacent cancer macrophages observed in the IHC 
assay were considered positive staining. Quantitative analysis 
of CD68 and CD206 in the stained sections was indepen-
dently performed by two pathologists blinded to the clinical 
data. The mean score of five high-power fields (HPF) (×400) 
was counted for each slide by an optical microscope of Leica 
(DM2500; Leica Microsystems, Wetzlar, Germany).
Follow up study. Follow-up evaluations were performed 
every 3 months for the first year and annually thereafter for 
locally advanced tumor stages. Among all the 268 patients, 
199 patients who completed the follow-up were further 
enrolled in survival analysis (69 cases were dropped). The 
scores of CD68-positive and CD206-positive were compared 
with demographical, clinical and histopathological character-
istics. All these variables were tested as predictors of patient's 
OS and DFS. OS was defined as the interval between the dates 
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of surgery and death or the last follow-up. DFS was defined as 
the interval between the dates of surgery and the first recur-
rence or the latest date of follow-up.
Statistical analysis. Statistical Package for Social Sciences 
version 16.0 (SPSS 16.0; SPSS Inc., Chicago, IL, uSA), 
MedCalc version 11.4.2.0 (MedCalc Software, Mariakerke, 
Belgium) and Graphpad Prism version 5.0 (Graphpad 
Software, Inc., La Jolla, CA, uSA) were used in the present 
study. Quantitative variables following a normal distribution 
were presented as mean ± standard deviation (SD), and the 
difference between/among groups were tested using t-test 
or one-way ANOVA. Quantitative variables with a skewed 
distribution were presented as medians with interquartile 
ranges (IQRs), and the differences between/among groups were 
tested using Mann-Whitney u test and Kruskal-Wallis test. 
Correlations of CD68/CD206-positive macrophages between 
the intratumor and the tumor adjacent tissue or between the 
two types of infiltrated macrophages were tested using the 
non-parametric Spearman's rank analysis. Then, the receiver 
operating characteristics (ROC) curve analysis was plotted 
to calculate the diagnostic accuracy of CD68 and CD206. 
The optimum cut-off value for diagnosis was determined by 
maximizing the sum of sensitivity and specificity. In addi-
tion, Kaplan-Meier survival curves and log-rank test were 
used to analyze the correlations between the CD68-positive 
and the CD206-positive macrophage numbers and survival of 
postsurgical HCC patients. Finally, Cox proportional hazards 
regression was employed for univariate and multivariate 
analysis of OS and DFS. Differences were considered statisti-
cally significant at two-sided P<0.05.
Results
The clinicopathological characteristics of HCC patients. This 
study comprised 268 patients with HCC and their clinico-
pathological parameters are given in Table I. The majority of 
cases were male (229, 85.4%) and nearly 50% of cases were 
aged under 54 years. Among the cases, near 80%  (209, 78%) 
had positive HBV and nearly half (112, 41.8%) HCC cases 
presented liver cirrhosis. Of these patients, 264 (98.51%) were 
considered early stage HCC: Child-Pugh-A (n=238, 88.8%), 
Child-Pugh-B (n=26, 9.7%) and Child-Pugh-C (n=4, 1.5%).
Distribution of CD68 and CD206 in HCC tissues and 
adjacent area. Liver histology results for CD68-positive and 
CD206-positive macrophages are depicted in Fig. 1. Among 
all specimens in our studies, CD68 expression was specific to 
macrophages and was shown in cell membrane and cytoplasm 
in brown color. Furthermore, the cells positively stained for 
CD206 often displayed typical macrophage morphology. 
CD68-positive and CD206-positive macrophages were infil-
trated in both primary tumor tissues (Fig. 1A and C) and tumor 
adjacent tissues (Fig. 1B and D). However, the adjacent tissue 
was infiltrated with higher density of both CD68-positive 
and CD206-positive macrophages compared with intratumor 
compartments (P<0.001 and P<0.001, respectively). The 
average levels of CD68 and CD206 staining are shown in 
Table IV. Additionally, in tumor adjacent tissues, the density of 
infiltrated CD68-positive macrophages was much higher than 
Table I. Clinicopathological characteristics of HCC patients.
Clinical variables n (%)
Sex
  Male 229 (85.4)
  Female 39 (14.6)
Age (years)
  <54 133 (49.6)
  ≥54 135 (50.4)
Alcohol intake
  Yes 95 (35.4)
  No 173 (64.6)
HBV
  Positive 209 (78.0)
  Negative 59 (22.0)
Liver cirrhosis
  Present 112 (41.8)
  Absent 156 (58.2)
PHT
  Present 19 (7.1)
  Absent 249 (92.9)
TBIL (µmol/l)
  <34 257 (95.9)
  ≥34 8 (3.0)
  NG 3 (1.1)
AFP (ng/ml)
  <400 161 (60.1)
  ≥400 107 (39.9)
Child-Pugh class
  A 238 (88.8)
  B 26 (9.7)
  C 4 (1.5)
Tumor size (cm)
  <5 130 (48.5)
  ≥5 138 (51.5)
Lymph node metastasis
  Present 4 (1.5)
  Absent 253 (94.4)
  NG 11 (4.1)
TNM stage
  I + II 203 (75.8)
  III + IV 65 (23.2)
Degree of histologic differentiation
  High 28 (10.5)
  Moderate 111 (41.4)
  Low 104 (38.8)
  NG 25 (9.3)
HBV, hepatitis B virus; PHT, portal hypertension; TBIL, total bili-
rubin; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis; NG, not 
get.
REN et al:  EXPRESSION OF CD68 AND CD206 IN HEPATOCELLuLAR CARCINOMA 889
that of CD206-positive macrophages (P<0.001) and the same 
pattern can be seen in the intratumor area (P<0.001).
Spearman's rank correlation coefficient analysis revealed 
a significant correlation in CD68 density between the 
intratumor tissues and the adjacent compartments (r=0.392; 
P<0.001; Fig. 2A). Similar results were obtained in the 
CD206-positive macrophages (r=0.360; P<0.001; Fig. 2B). 
This suggests a functional link between the intratumor 
macrophages and the adjacent macrophages. Notably, CD206 
expression was positively correlated with CD68 expression in 
both intratumor tissues (r=0.237; P<0.001; Fig. 2C) and adja-
cent tissues (r=0.261; P<0.001; Fig. 2D) from HCC patients. 
It may imply some interaction between CD68 and CD206 
cells.
Correlation of CD68/CD206 density with clinical 
characteristics. The relationship between the expression 
of CD68 and CD206 in HCC and the clinicopathological 
Figure 1. CD68-positive and CD206-positive macrophages in HCC tissues and adjacent tissues. Immunoreactivity to anti-CD68 (A and B) and anti-CD206 
(C and D) in tumor tissues (A and C) and adjacent tissues (B and D) of HCC.
Figure 2. Correlation between infiltrated CD68-positive and CD206-positive macrophages in different areas of HCC. (A) CD68 expression between intratumor 
tissues and adjacent tissues (r=0.392; P<0.001). (B) CD206 expression in intratumor tissues and adjacent tissues (r=0.360; P<0.001). (C) Positive correlation 
between CD206 and CD68 in intratumor tissues (r=0.237; P<0.001). (D) Positive correlation between CD206 and CD68 in adjacent tissues (r=0.261; P<0.001).
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features is listed in Tables II and III. We noted that a higher 
CD68 density was found in the older patients intratumorally 
(P=0.027). Cases with portal hypertension (PHT) appeared 
to have lower intratumor CD68 expression compared with 
Table II. Correlation of CD68-positive expression with clinicopathological characteristics of HCC patients.
 Intratumor CD68 Adjacent CD68 ------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
Clinical variables n Mean ± SD P-value n Mean ± SD P-value
Sex   0.125   0.142
  Male 190 65.42±32.11  206 77.62±23.04
  Female 35 74.71±36.18  37 83.62±21.47
Age (years)   0.027   0.893
  <54 106 61.86±27.53  117 78.45±22.66
  ≥54 118 71.42±36.66  125 78.85±23.10
Alcohol intake   0.901   0.258
  Yes 79 66.49±30.13  83 80.84±24.52
  No 146 67.07±34.36  160 77.34±21.95
HBV   0.954   0.030
  Positive 171 66.80±32.99  188 76.81±21.90
  Negative 54 67.09±32.77  55 84.42±25.26
Liver cirrhosis   0.633   0.946
  Present 91 65.59±34.68  103 78.65±22.68
  Absent 134 67.73±31.68  140 78.45±23.09
PHT   0.043   0.050
  Present 19 52.26±21.37  18 68.39±18.48
  Absent 206 68.21±33.45  225 79.35±23.03
TBIL   0.258   0.202
  <34 214 67.36±32.30  232 78.81±23.01
  ≥34 8 53.88±50.26  8 68.25±20.77
AFP (ng/ml)   0.008   0.026
  <400 133 62.03±30.84  146 75.88±23.18
  ≥400 92 73.86±34.59  97 82.54±21.91
Child-Pugh class   0.470   0.209
  A 197 67.60±32.73  215 79.20±22.82
  B 24 63.83±36.34  24 71.21±22.82
  C 4 48.75±4.43  4 86.50±22.25
Tumor size (cm)   0.072   0.012
  <5 103 62.74±33.33  107 75.57±21.46
  ≥5 115 70.66±31.21  127 83.00±23.34
Lymph node metastasis   0.654   0.523
  Present 8 72.00±26.67  8 83.63±12.31
  Absent 217 66.68±33.11  235 78.36±23.14
TNM stage   0.143   0.491
  I + II 168 64.99±33.84  185 77.97±23.37
  III + IV 57 72.39±29.40  58 80.34±21.29
Tumor differentiation   0.767   0.283
  Well 26 62.88±38.15  27 84.74±18.60
  Moderate 88 68.13±29.20  99 77.00±21.79
  Poor 91 67.21±33.43  94 79.01±24.02
SD, standard deviation; HBV, hepatitis B virus; PHT, portal hypertension; TBIL, total bilirubin; AFP, alpha-fetoprotein; TNM, tumor-node-
metastasis.
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those without PHT (P=0.043), but the difference in adjacent 
tumor data did not reach a statistical significance (P=0.050). 
Patients whose AFP concentration was >400 ng/ml might 
have much higher density of CD68 TAMs in both primary 
tumor tissues and tumor adjacent tissues (P=0.008 and 
P=0.026, respectively). Patients with high expression of CD68 
in tumor adjacent tissue were prone to have a larger tumor 
size (P=0.012). As for CD206, its density in adjacent tissue 
Table III. Correlation of CD206-positive expression with clinicopathological characteristics of HCC patients.
 Intratumor CD206 Adjacent CD206 ------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
Clinical variables n Mean ± SD P-value n Mean ± SD P-value
Sex   0.013   0.297
  Male 227 30.50±14.47  202 77.62±23.04
  Female 39 37.03±17.75  35 83.62±21.47
Age (years)   0.828   0.185
  <54 131 31.73±14.42  118 65.83±16.35
  ≥54 134 31.32±15.84  118 63.10±15.18
Alcohol intake   0.574   0.813
  Yes 93 32.14±13.76  84 64.73±15.67
  No 173 31.09±15.85  153 64.22±15.93
HBV   0.375   0.365
  Positive 208 31.02±14.84  183 63.89±15.88
  Negative 58 33.02±16.21  54 66.11±15.56
Liver cirrhosis   0.177   0.035
  Present 111 29.97±13.35  98 61.82±16.22
  Absent 155 32.52±16.25  139 66.22±15.30
PHT   0.971   0.240
  Present 19 31.58±10.89  13 59.38±18.38
  Absent 247 31.45±15.43  224 64.69±15.64
TBIL   0.349   0.007
  <34 255 31.15±15.19  228 64.74±15.61
  ≥34 8 36.25±13.51  6 47.00±16.86
AFP (ng/ml)   0.486   0.338
  <400 161 30.93±14.95  143 65.20±15.05
  ≥400 105 32.26±15.45  94 63.18±16.89
Child-Pugh class   0.001   0.240
  A 236 31.01±14.63  213 64.96±15.63
  B 26 31.27±13.22  21 58.86±15.86
  C 4 59.00±31.52  3 63.33±26.31
Tumor size (cm)   0.886   0.385
  <5 129 31.32±15.14  113 63.46±14.92
  ≥5 137 31.58±15.18  124 65.25±16.59
Lymph node metastasis   0.734   0.859
  Present 8 33.25±27.73  8 65.38±18.90
  Absent 258 31.40±14.67  229 64.36±15.73
TNM stage   0.357   0.013
  I + II 201 30.96±14.97  181 62.99±15.88
  III + IV 65 33.00±15.65  56 68.95±14.78
Tumor differentiation   0.445   0.644
  Well 28 28.07±10.65  24 66.08±13.39
  Moderate 111 31.72±13.47  99 65.07±15.34
  Poor 102 32.00±17.07  92 63.29±17.22
SD, standard deviation; HBV, hepatitis B virus; PHT, portal hypertension; TBIL, total bilirubin; AFP, alpha-fetoprotein; TNM, tumor-node-
metastasis.
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was significantly higher in patients with cirrhosis (P=0.035) 
or poor TNM stages (P=0.013). The HCC cases with younger 
age or better Child-Pugh class had lower intratumor CD206 
expression (P=0.001). Individuals with higher level of TBIL 
possessed decreased expression of CD206 (P=0.007) in 
tumor adjacent tissue. However, no statistical significance 
was observed in the expression of CD68 and CD206 with 
tumor differentiation, lymph node metastasis and alcohol 
intake.
Diagnostic prediction of CD68/CD206 staining for HCC. AFP 
is a valuable serological biomarker. A level >400 ng/ml was 
defined as cut-off value to evaluate sensitivity and specificity 
of CD68 and CD206. ROC curves showed that the optimal 
diagnostic cut-off for intratumor CD68 was 71/HPF [area 
under curve (AuC) 0.614, (95% CI, 0.547-0.678), sensitivity 
52.2% and specificity 70.7%; P=0.003], and that for adjacent 
area was 87/HPF [AuC 0.599, (0.534-0.661), 49.5 and 70.5%, 
P=0.008] (Fig. 3). In contrast, the optimal cut-off value for 
intratumor CD206 was 25/HPF [AuC 0.527, (0.465-0.588), 
sensitivity 56.2%, specificity 52.8%; P=0.463] while the 
value for tumor-adjacent area was 83/HPF [AuC 0.534, 
(0.469-0.599), 44.7, 69.2%; P=0.384] (Fig. 3).
Prognostic significance of CD206 and CD68 expression in 
HCC patients after operation. The prognostic value of CD68 
and CD206 expression in postsurgical HCC patients was 
examined and data are shown in Table V and Fig. 4. Within 
a median follow-up time of 44 months (1-54 months), 5-year 
OS and DFS rates for the 199 patients were 47 and 62%. The 
analyses showed that the median value for density of CD68 in 
intratumor was 61/HPF (CD68 density ≥61/HPF was defined 
as CD68high group, CD68 density <61/HPF was defined as 
CD68low group) and that in adjacent area was 78/HPF (CD68 
density ≥78/HPF was defined as CD68high group, CD68 
density <78/HPF was defined as CD68low group), respectively. 
Similarly, 29/HPF and 66/HPF were the medians of CD206 
macrophage content for the two areas.
Survival analyses revealed that high density of 
CD206-positive macrophages in intratumor tissues was 
significantly associated with reduced OS (P=0.013; Fig. 4E) 
and DFS (P=0.003; Fig. 4F) in post-surgical HCC patients. 
On the contrary, we noted that increased CD68-positive 
macrophages were significantly correlated with better 
survival only in tumor adjacent area (P=0.020; Fig. 4C) 
and patients with low CD68 expression in adjacent area 
exhibited a worse DFS (P=0.018; Fig. 4D). However, no 
significant correlations of CD68-positive macrophages 
infiltrated in intratumor (P=0.906 and P=0.535, respec-
tively; Fig. 4A and B) and CD206-positive macrophages in 
adjacent compartment with prognosis (P=0.330 and P=0.912, 
respectively; Fig. 4G and H). 
univariate analysis of prognostic factors revealed that 
CD68-positive macrophages in tumor adjacent tissue and 
CD206-positive macrophages in intratumor had significant 
prognostic effects on OS in post-surgical HCC patients 
(P=0.024 and P=0.014, respectively) (Table V). In addition, 
both low CD68 density in tumor adjacent tissue (P=0.008) 
and high CD206 density in intratumor (P=0.016) were 
identified as independent predictors of poor prognosis for 
OS by multivariate survival analysis after adjustment of 
covariates (Table V). Similar results were obtained for DFS. 
Increased CD68-positive macrophages in tumor adjacent 
tissue (P=0.016) and enhanced intratumor CD206-positive 
macrophages (P=0.003) played significant roles by univariate 
analysis. Multivariate survival analysis showed both CD68 
density in tumor adjacent tissue (P=0.028) and CD206 
density in intratumor tissue (P=0.005) could be as indepen-
dent predictors for DFS (Table V).
Combination of adjacent area CD68 density with intra-
tumoral CD206 density analysis. Patients were classified 
into four groups according to their intratumoral CD206 and 
adjacent tumoral CD68 densities (Table V): group I (n=65), 
low CD206 and CD68 density; group II (n=39), high CD206 
but low CD68 density; group III (n=46), low CD206 but high 
CD68 density; and group IV (n=49), high CD206 and CD68 
density. Differences in both OS (P=0.040; Fig. 5A) and DFS 
(P=0.015; Fig. 5B) were significant among the four groups and 
group II had the worst survival.
Figure 3. The optimal diagnostic cut-off for intratumor CD68 was 71/hpf and 
87/hpf for adjacent tumoral CD68 in the diagnosis of HCC.
Table IV. Difference in the density of CD68-positive and 
CD206-positive macrophages in tumor and adjacent tissue 
(mean ± SD).
 Density --------------------------------------
Staining n Mean ± SD P-value (paired t-test)
CD68   <0.001
  Intratumor 216 66.59±32.89
  Adjacent 216 79.41±23.42
CD206   <0.001
  Intratumor 236 31.55±15.03
  Adjacent 236 64.36±15.83
Intratumor   <0.001
  CD68 223 66.61±32.89
  CD206 223 30.42±15.13
Adjacent   <0.001
  CD68 220 79.89±22.64
  CD206 220 63.95±15.85
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Combination of adjacent area CD68 density/intratumoral 
CD206 density with HBV. To assess whether the combined 
use of adjacent area CD68 density and HBV infective status 
was better than either of these biomarkers alone, four groups 
were assessed as follows (Table V and Fig. 6): group I (n=69), 
high CD68 density and positive HBV; group II (n=27), high 
CD68 density but negative HBV; group III (n=80), low CD68 
density but positive HBV; and group IV (n=23), low CD68 
density and negative HBV. We found a significant difference 
in DFS (P=0.001; Fig. 6B), but not in OS (P=0.102; Fig. 6A) 
among the four groups. Group III with low CD68 density in 
adjacent tumor but positive HBV had the shortest recurrence 
time.
Similarly, another grouping approach is listed in Table V 
and Fig. 6C and D. There were significant differences in either 
OS (P=0.043; Fig. 6C) or DFS (P<0.001; Fig. 6D) among the 
four groups. Of note, group I had the poorest DFS. However, in 
univariate analysis, only difference in DFS (P<0.001) is shown 
in Table V. In brief, the combined predictive value in DFS was 
much greater than that of CD68 or CD206 alone.
Figure 4. OS and DFS for infiltrated CD206-positive and CD68-positive macrophages in different tumor areas of post-surgical HCC patients. In HCC patients 
after operation, the low CD68 expression in adjacent tumor and high density of CD206-positive macrophages in intratumor tissues were significantly associ-
ated with reduced OS and DFS (C-F). However, no significant association of CD68-positive macrophages infiltrated in intratumor and CD206-positive 
macrophages in adjacent compartment with prognosis was found (A, B, G and H).
ONCOLOGY REPORTS  38:  886-898,  2017894
Table V. univariate and multivariate analysis of different parameters with survival and recurrence in HCC patients.
 OS DFS --------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
 Multivariate Multivariate
 univariate --------------------------------------------------------- univariate ---------------------------------------------------------
Variables P-value HR 95% CI P-value P-value HR 95% CI P-value
Alcohol intake 0.257   NA 0.212   NA
  Yes vs. no
Smoking 0.012 1.717 1.069-2.759 0.025 0.866   NA
  Yes vs. no
HBV 0.212   NA 0.003 3.898 1.400-10.854 0.009
  Positive vs. negative
Liver cirrhosis 0.448   NA 0.961   NA
  Present vs. absent
PHT 0.436   NA 0.334   NA
  Present vs. absent
TBIL 0.867   NA 0.699   NA
  <34 vs. ≥34
Albumin 0.026 0.360 0.205-0.632 <0.001 0.280   NA
  <35 vs. ≥35
AFP 0.438   NA 0.206   NA
  <400 vs. ≥400
Child-Pugh class 0.740   NA 0.865   NA
  A vs. B vs. C
Tumor size 0.311   NA 0.936   NA
  <5 vs. ≥5
Lymph node metastasis <0.001 8.238 3.126-21.710 <0.001 0.460   NA
  Present vs. absent
Primary lesion <0.001 1.531 1.295-1.811 <0.001 0.054 1.214 1.001-1.473 0.049
TNM stage: <0.001 2.052 1.637-2.571 <0.001 0.326   NA
  I + I vs. III + IV
Tumor differentiation 0.421   NA 0.206   NA
  Well vs. moderate vs. poor
Intratumor features    NA    NA
  Low vs. high
CD68 density 0.907    0.538
CD206 density 0.014 1.792 1.116-2.879 0.016 0.003 2.222 1.280-3.856 0.005
Adjacent tumor features
  Low vs. high
CD68 density 0.024 0.510 0.311-0.837 0.008 0.016 0.529 0.299-0.935 0.028
CD206 density 0.334   NA 0.912   NA
Combine adjacent tumoral 0.040   NA 0.015   NA
CD68 and intratumoral CD206
Combine adjacent tumoral 0.014   NA 0.326   NA
CD68 and HBV
Combine intratumoral CD206 and HBV 0.070   NA <0.001   NA
OS, overall survival; DFS, disease-free survival; NA, not adopted; HBV, hepatitis B virus; PHT, portal hypertension; TBIL, total bilirubin; AFP, 
alpha-fetoprotein; TNM, tumor-node-metastasis; HR, hazard ratio; CI, confidence interval.
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Discussion
Results from the present study demonstrate that changes to 
CD68-positive and CD206-positive macrophage subpopula-
tions in tumor site and adjacent region in HCC are associated 
with OS and DFS. To the best of our knowledge, this is the 
first study that shows location-specific and subtype-specific 
macrophage expression and their prognostic values in HCC.
In the present study, the infiltrating CD68- and CD206-
positive subpopulations were observed in cancer tissues and 
in adjacent tissues of HCC, with predominant presence in 
the adjacent tumor tissues. CD68-positive macrophages were 
much more abundant than CD206-positive macrophages both 
in the intratumor and adjacent areas. This is in accordance with 
the fact that the total number of CD68-positive macrophages 
is greater than that of CD206-positive M2 macrophages. 
According to the infiltrating macrophage count, there was a 
notable increase of CD68 expression in non-tumor tissues in line 
with the increased macrophage expression and inflammatory 
response in HCC demonstrated previously by others (25,26). 
This result is in contrast to several investigations which 
showed overexpression of CD68 in tumor tissue (27). This 
suggests the expression profile of CD68 in tumor and adjacent 
tumor-free region is specific to HCC. The increased number of 
CD68-positive macrophages in HCC adjacent samples in our 
analysis may be explained by heterogeneity of macrophages 
in response to different microenvironment signals. Thus, the 
subtype of CD68-positive macrophages in adjacent tissue is 
probably different from that in intratumor tissue and they 
may represent resident macrophages (CD68-positive Kupffer 
Figure 5. OS and DFS for combination of adjacent tumoral CD68 density with intratumoral CD206 density. Combined analysis of adjacent tumoral CD68 with 
intratumoral CD206, differences in both OS (A) and DFS (B) were significant.
Figure 6. OS and DFS for combination of adjacent tumoral CD68 density/intratumoral CD206 density with HBV. Combination of either adjacent CD68 or 
intratumoral CD206 with HBV, was significantly different in DFS (B and D). There was significant difference in OS for the combination of intratumoral 
CD206 with HBV (C), but not for combination of either adjacent CD68 or HBV (A).
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cells). Specifically, CD68-positive macrophages in adjacent 
tumor are more similar to macrophages in normal or inflamed 
tissues that possess spontaneous antitumor activity. Therefore, 
these cells would be beneficial in the prognosis of HCC (28). 
These data suggest a possibility that as a front line defense to 
prevent tumor growth, the adjacent non-tumor liver tissue is 
endowed with abundant CD68-positive macrophages. Positive 
correlation of increased amount of adjacent CD68-positive 
macrophages with good HCC prognosis in the present study 
could be explained by the ability of macrophages that are not 
yet re-programmed by tumor cells to kill cancer cells. In other 
words, CD68-positive macrophages in adjacent tissue may 
have antitumor activity as they are uneducated into M2 pheno-
type by cancer, while in tumor the opposite happens. In tumor 
area, a genetic exchange between the primary tumor cells and 
the associated macrophages may lead to the expression of a 
more invasive phenotype of macrophages. On the other hand, 
immunohistochemistry with antibodies to CD206 also identi-
fied a higher CD206 density in adjacent tissue in HCC patients, 
which is similar to a study examining the higher proliferation 
of endothelial cells to IL-6/sIL-6R in HCC peritumor (29). 
Generally, CD206 can identify mannose and fucose glyco-
conjugates and has been recognized as an important regulator 
in the phagocytosis of intracellular pathogens. Herein we 
speculate that this phagocytosis in tumor may consume a 
large number of CD206 so that the count of CD206 would be 
reduced dramatically in intratumor. However, the mechanism 
for overexpression of CD68 and higher density of CD206 in the 
adjacent liver tissue remains unclear. One possible mechanism 
is tumor cell-micro environmental crosstalk which is complex. 
Another possibility is that a line of defense surrounding 
tumor formed by tumor microenvironment may block the 
entrance of macrophages into the tumor. Furthermore, the 
tumor itself could be a possible stimulator either stimulating 
chronic inflammation or causing a host hepatocyte reac-
tion (26), resulting in elevated production of cytokines and 
more CD68/CD206 at the tumor-host margin. Moreover, the 
heterogeneity of macrophages in HCC raises a further possi-
bility that there are different distributions and phenotypes of 
macrophages in different tumor parts and nearby areas. We 
propose that some genetic heterogeneity among different indi-
viduals may lead to the different baseline expression level of 
CD68/CD206. In this regard, previous evidence concerning 
the density of TAMs in HCC partly contrasts with our data. 
These discrepancies could be due to differences in the meth-
odology, sample types, or patient characteristics. Two recent 
studies showed no association of CD68-positive macrophages 
in tumor region with clinicopathological characteristics in 
HCC but the tumor-adjacent region was not examined (30,31). 
Additionally, associations between CD68-positive and 
CD206-positive macrophages in both tumor and adjacent 
tissues were also found in this study. A similar relationship 
between CD68-positive and CD163-positive macrophages in 
HCC was also previously reported (21). This may suggest a 
possible interaction between macrophage subpopulations.
In the present study, low CD68 expression in tumor was 
associated with age and PHT, which could partly explain 
the protective role of CD68 in this study. On the contrary, 
patients with cirrhosis, poor TNM stages and Child-Pugh class 
tended to have high CD206 density, indicating the M2 role of 
CD206 in cancers. On the whole, a lower correlation between 
CD68-positive/CD206-positive macrophages and clinico-
pathological characteristics in HCC patients may imply some 
other genetic heterogeneity within different individuals. Our 
results also suggest that CD68 expression either in intratumor 
or in adjacent tumor may be a potential diagnostic measure 
of HCC. However, the effectiveness of this emerging marker 
requires further assessment.
Prognostic factors are of paramount interest in the risk 
assessment of cancer patients. This study demonstrated that the 
dense CD68 infiltration in the tumor adjacent tissues, but not in 
primary tumor tissues, was strongly associated with favorable 
survival of both OS and DFS for post-operative HCC patients 
in univariate and multivariate analyses. This is consistent with 
another report on esophageal squamous cell carcinoma (32). 
However, CD68 has been frequently shown to correlate with 
an adverse prognosis in a variety of malignancies, such as oral 
squamous cell carcinoma and HCC (21-24). Recently, dual 
prognostic significance of CD68-positive TAMs has been 
reported in pancreatic ductal adenocarcinoma (PDAC) (33). 
In this study, CD68-TAMs at the tumor-stroma interface 
may promote PDAC distant metastasis, while in patients who 
have received chemotherapy, TAMs play an opposite role. 
Additionally, some authors suggested that CD68-positive 
macrophages did not affect the outcome of patients with clas-
sical Hodgkin lymphoma (34). A similar finding was reported 
recently by Shu et al (30), however, we thought that the results 
could not comprehensively and accurately reveal the prog-
nostic value of CD68 as they only analyzed HCC tissues for 
CD68-positive macrophages rather than adjacent tissues.
Macrophages in normal or inflamed tissues possess spon-
taneous antitumor activity, while TAMs seem to have distinct 
phenotypes with diverse functional programs within different 
local environment (28). This might suggest that CD68-positive 
macrophages, exhibiting M1-like phenotype, serve as a protec-
tive phenotype and likely lessen HCC damage. Moreover, 
TAMs in HCC are heterogeneous and present different 
phenotypes as heterogeneity and plasticity are hallmarks of 
macrophages (22). Possibly, there was different depletion or 
recruitment of heterogeneous populations of protumor and 
antitumor macrophages in the liver. Also, plasticity of macro-
phages allowed them to acquire either protumor or antitumor 
functions (35). Thus, it was not surprising to find various 
functional phenotypes of macrophages in adjacent tissue 
versus intratumor tissue, as seen in the present study. Positive 
correlation of increased amount of adjacent CD68-positive 
macrophages with HCC prognosis in this study could be due 
to the macrophages that were not yet re-programmed into M2 
phenotype by tumor cells and still possessed the ability of 
killing cancer cells.
In our HCC patient cohort, the increased CD206-positive 
M2 macrophages at primary tumor tissues were correlated 
with poor prognosis. The bulk of available information indi-
cates that CD206-positive M2 macrophages appear to possess 
mostly tumor promoting property (36,37). This is in line with 
a poor prognosis and hence the prognostic value of intratumor 
CD206 macrophages in HCC patients. Although intratumoral 
CD206-positive M2-macrophages were reported to promote 
tumor cell dissemination, the adjacent CD206-positive 
macrophages may play a different, even opposite role. Herein, 
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intratumoral CD206-positive macrophages contributed to a 
propensity of metastases and poor prognosis for HCC. Our 
results strongly demonstrate that intratumoral CD206 is an 
independent factor of prognosis for postsurgical HCC patients. 
In contrast, another study reported an association of decreased 
CD206-positive macrophages with loss of interstitial cells 
of Cajal in patients with diabetic gastroparesis, indicating a 
cytoprotective role for CD206-positive macrophages (38). 
These data may prompt a therapeutic strategy that targets 
intratumoral CD206 by reprogramming its protumor pheno-
type into an effective antitumor activity. Our findings with 
CD206-positive macrophages are consistent with two recent 
reports that CD206 in tumor region of HCC was linked to poor 
prognosis. However, by examining CD68/CD206-positive 
macrophages in both tumor tissues and adjacent tissues, our 
models have higher predicative power.
Furthermore, we found a much greater advantage in 
combining capability of intratumor CD206 with adjacent 
CD68 in prognostic prediction of HCC. There are greater 
numbers of younger patients with HBV-related HCC in 
Asian countries including China (39), as shown in the present 
study (Table I). The findings revealed a better prognostic 
value, especially in recurrence. According to the Cox regres-
sion model that included the levels of CD68/CD206-positive 
macrophage content, smoking, HBV, albumin, lymph node 
metastasis, primary lesion and TNM, it was concluded that 
primary lesion, adjacent CD68 and intratumor CD206 were 
independent prognostic factors for both OS and DFS.
In conclusion, this study clearly demonstrates higher densi-
ties of CD68 and CD206 in the adjacent liver tissue than those 
in tumor tissue. The dense CD206 macrophage infiltration 
at the tumor is an independent predictor of poor survival in 
postsurgical HCC patients. High density of CD68 macrophage 
infiltration in adjacent tissue is capable of predicting improved 
survival. The findings from this study suggest the complexity 
of macrophages within and surrounding tumor microenviron-
ment, a novel role for CD68/CD206-positive macrophages and 
a basis for targeting these cells as new therapeutic strategies 
for HCC patients.
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